MapLight Therapeutics, Inc. (MPLT) intrinsic value & 10-year financials
MapLight Therapeutics, Inc. (MPLT) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $7.70
- Market cap
- $66.8M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -67.5%
- Free cash flow (FY2025)
- -$138.6M
MPLT 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$161.2M | -$18.56 | -$138.6M | — | -169.2% |
| FY2024 | — | -$77.6M | -$8.78 | -$79.6M | — | 34.3% |
| FY2023 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
MapLight Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
MapLight Therapeutics, Inc. has earned high returns on invested capital, averaging 16.3% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
MapLight Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
MapLight Therapeutics, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.